Navigation Links
The Reality of Pregnancy in Sub-Saharan Africa: Author Shares Truth About Pregnancy in a Region Where 1 in 16 Women Die from Complications
Date:12/10/2007

SYLVANIA, Ohio, Dec. 10 /PRNewswire/ -- Pregnancy: Typically, it is an event in a woman's life that calls for happiness. There is great joy in anticipating the arrival of a new baby into the world, and it is usually an uneventful experience, especially in the Western world. When problems do happen to arise, help is readily available.

But this view of pregnancy stands in stark contrast to many of the experiences in the Sub-Saharan region of Africa, where pregnancy is a source of great pain and suffering for the vast majority of women. Dr. Benjamin Ogbonna reveals the truth about a situation where 1 in 16 women die from complications of pregnancy in his new book, "Pregnancy: A continuing source of sorrow and pain for women in Sub-Saharan Africa" (published by AuthorHouse - http://www.authorhouse.com).

Drawing upon his experiences with the subject on three continents - Africa, Europe and Asia - Dr. Ogbonna, brings maternal deaths in Sub-Saharan Africa to the front burner, sparing no detail. Written with the general public in mind, "Pregnancy" uses as little medical terminology as possible due to the importance of reaching a wide audience.

"It should make an interesting reading for people in the western world to enable them to full appreciate what is happening in other places," Dr. Ogbonna writes. "For people in Sub-Saharan Africa, it is a book that is intended to rouse them from their protracted slumber to enable them to appreciate that there is a problem that needs urgent attention."

Dr. Ogbonna discusses the various causes of maternal deaths and possible solutions to the serious problem. He seeks not only to educate the women in the region about the reasons why many of them die in pregnancy and how to avoid such deaths, but also the region's elected leaders. The book acknowledges the efforts of charitable organizations around the world who have been actively involved in reducing
'/>"/>

SOURCE AuthorHouse
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Sleep Disorders: Waking Up to Reality
2. Families Face Harsh Reality: 2,000 Children Join the Uninsured Each Day
3. Virtual Reality Technology Finds Ready and Willing Market in Healthcare
4. Audiences Nationwide Will Awake to a Frightening Reality on November 30th
5. Non-Invasive Fat-Melting Procedures - Hype or Reality?
6. AUDIO from Medialink and Reality Coalition: Promoting a Healthier Workforce
7. UCLA mathematician works to make virtual surgery a reality
8. HIV therapy in pregnancy-data support WHO recommendations
9. Treating diabetes during pregnancy can break link to childhood obesity
10. Treating Diabetes During Pregnancy Could Lead to Thinner Kids
11. 15% of Women Struggle With Pregnancy-Related Depression
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10New study suggests the brain predicts what eyes in motion will see 55304 1New study suggests the brain predicts what eyes in motion will see 55304 2SRNL automakers to develop high performance wireless sensors networks 9693 1SRNL automakers to develop high performance wireless sensors networks 9693 2SRNL automakers to develop high performance wireless sensors networks 9693 3New Data Show ChloraPrep 28R 29 Significantly More Effective Than DuraPrep 28TM 29 and Povidone Iodine in Eliminating Bacteria From Skin Prior to Shou 55300 1New Data Show ChloraPrep 28R 29 Significantly More Effective Than DuraPrep 28TM 29 and Povidone Iodine in Eliminating Bacteria From Skin Prior to Shou 55300 2New Data Show ChloraPrep 28R 29 Significantly More Effective Than DuraPrep 28TM 29 and Povidone Iodine in Eliminating Bacteria From Skin Prior to Shou 55300 3New Data Show ChloraPrep 28R 29 Significantly More Effective Than DuraPrep 28TM 29 and Povidone Iodine in Eliminating Bacteria From Skin Prior to Shou 55300 4New Data Show ChloraPrep 28R 29 Significantly More Effective Than DuraPrep 28TM 29 and Povidone Iodine in Eliminating Bacteria From Skin Prior to Shou 55300 5